1. Search Result
Search Result
Results for "

Acs pubs hsp Inhibitors

" in MedChemExpress (MCE) Product Catalog:

448

Inhibitors & Agonists

4

Fluorescent Dyes

10

Biochemical Assay Reagents

16

Peptides

42

Natural
Products

52

Recombinant Proteins

9

Isotope-Labeled Compounds

84

Antibodies

5

Click Chemistry

11

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15190
    NVP-HSP990
    4 Publications Verification

    hsp-990

    HSP Apoptosis Cancer
    NVP-HSP990 is a potent, selective and orally active Hsp90 inhibitor, with IC50 values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.
    NVP-HSP990
  • HY-P2832

    Acs

    Endogenous Metabolite Metabolic Disease Cancer
    Acyl coenzyme A synthetase (ACS), namely acetyl coenzyme A synthetase, is often used in biochemical research. Acyl coenzyme A synthetase can catalyze the activation of fatty acids by coenzyme A through a two-step thioesterification reaction to produce acyl coenzyme A, and then participate in a variety of anabolic and catabolic lipid metabolism pathways, and participate in the TCA cycle in aerobic respiration .
    Acyl coenzyme A synthetase
  • HY-124653
    HSP27 inhibitor J2
    5+ Cited Publications

    J2

    HSP Cancer
    HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition .
    HSP27 inhibitor J2
  • HY-115997

    PROTACs HSP Cancer
    PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC50=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PROTAC HSP90 degrader BP3
  • HY-B0658A

    Zinc(II) acetate dihydrate, Acs, 98%

    Biochemical Assay Reagents Others
    Zinc acetate dihydrate, ACS, 98% (Zinc (II) acetate dihydrate, ACS, 98%) acts as a metal chelator and an intestinal metallothionein inducer. Zinc acetate dihydrate, ACS, 98% induces intestinal metallothionein synthesis and shortens the course of the common cold. Zinc acetate dihydrate, ACS, 98% is applicable to the research of copper metabolism disorder-related diseases, the common cold and Wilson's disease, as well as protein experiments .
    Zinc acetate dihydrate, ACS, 98%
  • HY-Y0537K

    Biochemical Assay Reagents Cardiovascular Disease
    Potassium chloride, ACS, 99.0% is a metal halide salt composed of potassium and chlorine. Potassium chloride, ACS, 99.0% replenishes electrolytes, corrects water-electrolyte imbalance, and is used in hypokalemia research. Potassium chloride, ACS, 99.0% is also used to prepare buffer solutions and produce fertilizers, with applications in the fields of medicine, scientific research and food processing. Potassium chloride, ACS, 99.0% plays a key role in protein extraction and dissolution .
    Potassium chloride, ACS, 99.0%
  • HY-148215A

    HSP Neurological Disease Cancer
    Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17 hydrochloride
  • HY-12622
    HSP70-IN-1
    1 Publications Verification

    HSP Cancer
    HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC50 of 2.3 μM.
    HSP70-IN-1
  • HY-B2217D

    Bacterial Biochemical Assay Reagents Inflammation/Immunology
    Calcium hydroxide, ACS, 95% has high bactericidal activity and high pH. Calcium hydroxide, ACS, 95% has ability to induce hard tissue formation. Calcium hydroxide, ACS, 95% can dissociate into calcium (Ca) and hydroxyl ions (OH). Calcium hydroxide, ACS, 95% has the potential for intra-canal medicament research .
    Calcium hydroxide, ACS, 95%
  • HY-P2827

    Acs

    Acetyl-CoA synthetase Cancer
    Acetyl-CoA synthetase (ACS) is a key enzyme that catalyzes the conversion of acetate to acetyl-CoA (Ac-CoA). Acetyl-CoA synthetase catalyzes the formation of thioester bonds between coenzyme A and carboxylic acids, while simultaneously hydrolyzing ATP into AMP and pyrophosphate .
    Acetyl-CoA synthetase
  • HY-W107935

    HSP Cancer
    Hsp90-IN-37 (Z-2) is a heat shock protein 90 (Hsp90) inhibitor that inhibits Hsp90 enzymatic activity by 69%. Hsp90-IN-37 has antitumor activity .
    Hsp90-IN-37
  • HY-149891

    HSP Cancer
    HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC50 of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .
    HSP90-IN-23
  • HY-170944

    HSP Apoptosis Caspase Cancer
    BAG3/HSP70-IN-1 (compound 16) is the first-in-class BAG3 and HSP70 dual inhibitor. BAG3/HSP70-IN-1 binds to BAG3 full-length, BAG3-BD, and HSP70 proteins with Kds of 33.10 μM, 27.90 μM, and 33.80 μM, respectively. BAG3/HSP70-IN-1 inhibits HeLa cells with an IC50 of 49.46 μM. BAG3/HSP70-IN-1 induces apoptosis by activating caspase 3 and caspase 9 levels in HeLa cells. BAG3/HSP70-IN-1 elevates p21 levels while reduces FOXM1 expression in HeLa cells. BAG3/HSP70-IN-1 decreases ATPase activity .
    BAG3/HSP70-IN-1
  • HY-111414

    HSP Cancer
    Hsp90-Cdc37-IN-1 is an Hsp90-Cdc37 interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC50 of 140 nM.
    Hsp90-Cdc37-IN-1
  • HY-153588

    HSP Cancer
    HSP90-IN-22 (Compound 35) is an Hsp90 inhibitor with antiproliferative properties on cells with IC50 values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells, respectively.
    HSP90-IN-22
  • HY-179561

    Drug Derivative Cardiovascular Disease
    ACS14 is a derivative of Aspirin (HY-14654). ACS14 reduces Buthionine Sulfoximine (BSO) (HY-106376)-induced hypertension, plasma levels of thromboxane B2, 8-isoprostane, and insulin in rats, while GSH remained in the control range. ACS14 can be used for hypertension research .
    ACS14
  • HY-15035

    Acs 15; ATB-337

    MDM-2/p53 JNK SOD Cardiovascular Disease Inflammation/Immunology
    S-Diclofenac (ACS 15) is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac activates the p53 signaling pathway, and inhibits the activation of JNK. S-Diclofenac exhibits antioxidant and anti-inflammatory activities .
    S-Diclofenac
  • HY-146325

    HSP Cancer
    HSP90-IN-11 (Compound 12c) is a potent inhibitor of HSP90. HSP90-IN-11 displays potent HSP90α inhibition comparable to AUY-922 (Luminespib). HSP90-IN-11 shows significant antiproliferative activity in CRC and NSCLC cells in a double digit nM range. HSP90-IN-11 leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. HSP90-IN-11 induces significant accumulation of a sub-G1 phase population .
    HSP90-IN-11
  • HY-175865

    HSP Apoptosis Cancer
    HSP70-IN-7 is a nonselective HSP70 inhibitor with Kds of 4.71, 2.16 and 2.93μM against HSP70, GRP75, and GRP78. HSP70-IN-7 exhibits selective toxicity against breast cancer cells, induces cell apoptosis and effectively suppresses the properties of breast cancer stem cells (BCSCs). HSP70-IN-7 can be used for the study of breast cancer .
    HSP70-IN-7
  • HY-146228

    HSP Apoptosis Topoisomerase EGFR VEGFR Cancer
    HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC50 value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .
    HSP90-IN-13
  • HY-176279

    HSP Cancer
    Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC50=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .
    Hsp90-IN-42
  • HY-163854

    HSP Bcl-2 Family Apoptosis Cancer
    HSP70-IN-6 (Compound JL-15) is an inhibitor of Hsp70-Bim protein-protein interaction (PPI) (IC50: 70 nM). HSP70-IN-6 induces apoptosis in chronic myeloid leukemia (CML) cells, with EC50s of 0.43 μM(BV173), 0.88 μM (K562), 0.19 μM (K562-R3) .
    HSP70-IN-6
  • HY-144650

    Apoptosis HSP Cancer
    Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits Hsp90Cdc37 by covalent-binding, and induces apoptosis .
    Hsp90-Cdc37-IN-3
  • HY-W009722A

    Ditiocarb sodium trihydrate, Acs, 99.0%

    HIV Biochemical Assay Reagents Infection
    Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% (Ditiocarb sodium trihydrate, ACS, 99.0%) is a copper reagent. The reaction with Cu 2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer .
    Sodium diethylcarbamodithioate trihydrate, ACS, 99.0%
  • HY-174476

    HSP Drug Intermediate Cancer
    HSP90i is a HSP90 inhibitor. HSP90i can be used as a drug intermediate to synthesize LYTACs, such as dPDL1-4 (HY-174468) .
    HSP90i
  • HY-143400

    HSP Hedgehog Cancer
    HSP70-IN-3 is a potent HSP70 inhibitor (IC50s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 .
    HSP70-IN-3
  • HY-178462

    HSP DNA/RNA Synthesis Cancer
    Hsp70/FoxM1-IN-1 (Compound 7d) is a potent heat shock protein 70 (Hsp70) and Forkhead box M1 (FoxM1) dual inhibitor. Hsp70/FoxM1-IN-1 demonstrates significant antiproliferative and pro-apoptotic effects in multiple solid tumor models (e.g., breast, colorectal cancer), particularly for tumors co-overexpressing Hsp70/FoxM1 .
    Hsp70/FoxM1-IN-1
  • HY-113574

    HSP Cancer
    HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective HSP-90 inhibitor with an IC50 value of 30 nM. HSP90-IN-29 has antitumor activity .
    HSP90-IN-29
  • HY-Y1175A

    Biochemical Assay Reagents Others
    Calcium acetate monohydrate, ACS, 99% is a monohydrate form of calcium acetate used to precipitate oxalates in solution; it also serves as a stabilizer, buffer, and chelating agent.
    Calcium acetate monohydrate,ACS, 99%
  • HY-170326

    Ligands for Target Protein for PROTAC HSP Cancer
    Hsp90-in-35 (Compound 379) is an inhibitor of Hsp90. The IC50 of HSP90-IN-35 for Her2 is between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize PROTAC (HY-153881) .
    HSP90-IN-35
  • HY-144724

    HSP Apoptosis Cancer
    HSP90-IN-10 (Compound 16s) is a potent inhibitor of HSP90. HSP90-IN-10 exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC50 value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .
    HSP90-IN-10
  • HY-171755

    HSP Cancer
    Hsp90-IN-40 (Compound 15b) is a heat shock protein 90 (Hsp90) C-terminal inhibitor. Hsp90-IN-40 exhibits antiproliferative activity against SKBr3 and MCF-7 breast cancer cells (IC50 of 2.57 µM and 2.43 µM, respectively). Hsp90-IN-40 inhibits cancer cell growth by inhibiting the Hsp90 C-terminal function, leading to Hsp90-dependent protein degradation. Hsp90-IN-40 can be used in breast cancer research .
    Hsp90-IN-40
  • HY-150655

    HSP Cancer
    Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell .
    Hsp90-IN-15
  • HY-168205

    HSP Apoptosis Cancer
    HSP90-IN-33 (compound 24e) is a potent Hsp90 inhibitor with Kd values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .
    HSP90-IN-33
  • HY-145814

    HSP Fungal Infection
    HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .
    HSP90-IN-9
  • HY-148963

    HSP Cancer
    HSP90-IN-20 (compound 78p) is a potent HSP90 inhibitor with an IC50 of ≤10 μM. HSP90-IN-20 has the potential for cancers research .
    HSP90-IN-20
  • HY-170895

    HSP Na+/K+ ATPase Cancer
    Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong HSP90 binding affinity with a Kd of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC50 of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC50s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively .
    Hsp90-IN-38
  • HY-170910

    HSP Cancer
    Hsp90-IN-39 (Compound 16t) is a HSP90 inhibitor with notable selectivity for the HSP90α isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .
    Hsp90-IN-39
  • HY-P10541

    HSP Others
    HSP70/DnaK substrate peptide is a short peptide that the HSP70/DnaK molecular chaperone can bind and act on. HSP70/DnaK substrate peptide can be used to study the mechanism of action of HSP70/DnaK in molecular chaperone function .
    HSP70/DnaK substrate peptide
  • HY-177042

    HSP Fungal Infection Cancer
    Hsp90-IN-41 (Compound C1) is an inhibitor of Hsp90 (IC50 = 0.044 μM). Hsp90-IN-41 exhibits antifungal and antitumor (IC50 = 0.049 μM) activities in vitro .
    Hsp90-IN-41
  • HY-151137

    mTOR HSP Apoptosis Autophagy Cancer
    HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and mTOR inhibitor with IC50 values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .
    HSP90/mTOR-IN-1
  • HY-P10541A

    HSP Others
    HSP70/DnaK substrate peptide TFA is a short peptide that the HSP70/DnaK molecular chaperone can bind and act on. HSP70/DnaK substrate peptide TFA can be used to study the mechanism of action of HSP70/DnaK in molecular chaperone function .
    HSP70/DnaK substrate peptide TFA
  • HY-148215

    HSP Cancer
    Hsp90-IN-17 (Example 5) is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17
  • HY-173337

    HSP Interleukin Related Cancer
    HSP90α-IN-1 is a HSP90α inhibitor (IC50 = 111 nM) that exhibits senolytic activity across various cellular senescence models. HSP90α-IN-1 is related to the xanthinic family. HSP90α-IN-1 is involved in research on combating age-related inflammaging and diseases, including cancer, and possibly extend a healthy lifespan .
    HSP90α-IN-1
  • HY-179377

    HSP Tau Protein Neurological Disease
    Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC50 being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .
    Aha1/Hsp90-IN-2
  • HY-179012

    APC CDK Raf Akt HSP Cancer
    CDC20/HSP90-IN-1 (Compound 2b) is a Cdc20/Hsp90 inhibitor with a Kd of 16.2 μM for Cdc20 and a Kd of 0.241 μM for Hsp90α. CDC20/HSP90-IN-1 exerts potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. CDC20/HSP90-IN-1 overcomes Vemurafenib (HY-12057)-induced resistant melanoma .
    CDC20/HSP90-IN-1
  • HY-158131

    FKBP HSP Neurological Disease Cancer
    FKBP51-Hsp90-IN-2 (Compound E08) is a selective FKBP51-Hsp90 protein-protein interaction inhibitor with IC50 values of 0.4 µM and 5 µM for FKBP51 and FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .
    FKBP51-Hsp90-IN-2
  • HY-147974

    HSP Influenza Virus Infection
    HSP90-IN-14 (compound 4) is a potent Hsp90 (heat shock protein 90) inhibitor, with a Kd of 0.26 μM. HSP90-IN-14 shows anti-influenza virus activity in MDCK cells, with EC50 values of 2.6, 3.9, and 17 μM for influenza A/H3N2, A/H1N1, and B, respectively .
    HSP90-IN-14
  • HY-149638

    Sirtuin HSP Cancer
    HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity .
    HSP70/SIRT2-IN-2
  • HY-149637

    Sirtuin HSP Cancer
    HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity .
    HSP70/SIRT2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: